TY - JOUR
T1 - New concepts in antimicrobial resistance in cystic fibrosis respiratory infections
AU - Drevinek, Pavel
AU - Canton, Rafael
AU - Johansen, Helle Krogh
AU - Hoffman, Lucas
AU - Coenye, Tom
AU - Burgel, Pierre-Regis
AU - Davies, Jane C
N1 - Copyright © 2022. Published by Elsevier B.V.
PY - 2022/11
Y1 - 2022/11
N2 - In this review, we summarize the main points that were raised and highlighted during the pre-conference meeting to the 17th European Cystic Fibrosis Society Basic Science Conference, held from 30 March to 2 April, 2022 in Albufeira, Portugal. Keynote lectures provided an update on the latest information regarding the phenomenon of antimicrobial resistance (AMR) in cystic fibrosis (CF). Traditional themes such as in vitro antibiotic susceptibility testing and its clinical value, AMR evolution in persistent Pseudomonas aeruginosa infection and the impact of biofilm on AMR were discussed. In addition, the report gives an overview on very recent AMR-related topics that include an ecological view of AMR in CF lung, referred to as resistome, and novel anti-infective approaches in preclinical or early clinical research such as antibiofilm drugs and bacteriophages.
AB - In this review, we summarize the main points that were raised and highlighted during the pre-conference meeting to the 17th European Cystic Fibrosis Society Basic Science Conference, held from 30 March to 2 April, 2022 in Albufeira, Portugal. Keynote lectures provided an update on the latest information regarding the phenomenon of antimicrobial resistance (AMR) in cystic fibrosis (CF). Traditional themes such as in vitro antibiotic susceptibility testing and its clinical value, AMR evolution in persistent Pseudomonas aeruginosa infection and the impact of biofilm on AMR were discussed. In addition, the report gives an overview on very recent AMR-related topics that include an ecological view of AMR in CF lung, referred to as resistome, and novel anti-infective approaches in preclinical or early clinical research such as antibiofilm drugs and bacteriophages.
KW - Anti-Bacterial Agents/pharmacology
KW - Cystic Fibrosis/complications
KW - Drug Resistance, Bacterial
KW - Humans
KW - Microbial Sensitivity Tests
KW - Pseudomonas Infections/diagnosis
KW - Pseudomonas aeruginosa
KW - Respiratory Tract Infections/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85140054898&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2022.10.005
DO - 10.1016/j.jcf.2022.10.005
M3 - Review
C2 - 36270946
SN - 1569-1993
VL - 21
SP - 937
EP - 945
JO - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
JF - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
IS - 6
ER -